Therapeutic areas

We’re harnessing our deep knowledge of inflammatory mechanisms and the science of the immune system to redefine the future of respiratory medicine and target lung, liver and kidney disease.

Our ambition is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and women’s cancers into lung and gastrointestinal cancers, as well as other solid tumours.

We’re leaders in HIV, focused on ending the global epidemic. We have an industry-leading pipeline, driven by patient insights.

Our infectious diseases portfolio, and including HIV, is the broadest in the industry.